19 March 2025
SOFTCAT plc (‘Softcat’, the ‘Group’) Half year results for the six months to 31 January 2025 Strong first half performance with positive momentum Softcat…
18 March 2025
HARWORTH GROUP PLC (‘Harworth’ or the ‘Group’ or the ‘Company’) Full Year Results for the year ended 31 December 2024 Operational outperformance, strong returns…
17 March 2025
F&C INVESTMENT TRUST PLC Audited Statement of Results for the year ended 31 December 2024 F&C Investment Trust plc (‘F&C’/the ‘Company’) today announces its…
Full Year results for the 12 months ended 31 December 2024 Resilient performance in 2024 with strong foundations in place to drive medium-term outperformance…
Eneboparatide met primary endpoint of normalising serum calcium in adults with hypoparathyroidism at 24 weeks in CALYPSO Phase III trial Trial continues as planned…
Imfinzi approved in the EU as first and only immunotherapy for limited-stage small cell lung cancer Approval based on ADRIATIC Phase III trial results which…
AstraZeneca to acquire EsoBiotec to advance cell therapy ambition Acquisition includes world-leading in vivo delivery platform with potential to transform cell therapy AstraZeneca has…
13 March 2025
Amsterdam, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 13 March 2025 – Euronext announces that it has entered into a definitive agreement with Visma to…